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Introduction
Amniotic fluid contains a heterogeneous population of
cells of fetal origin. Potential sources contributing to the
presence of cells in amniotic fluid are the fetal skin, the
fetal membranes of placenta, and the epithelial and
mucosa of the fetal digestive, respiratory and urinary
tracts [1–3]. We previously developed a two-stage 
culture protocol to isolate a population of amniotic
fluid-derived mesenchymal stem cells (AFMSCs) from
second-trimester amniocentesis [4]. We further re-
ported that human amniotic fluid contains a subpop-
ulation of clonally multipotent fetal stem cells. Besides
the common mesenchymal lineages, they also have the
capacity to differentiate into multiple neural lineages
and release dopamine in vitro. These findings supported
the idea that human amniotic fluid provides a great
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SUMMARY
Objective: The aim of this study was to verify the existence of a side population (SP) of cells in second-trimester
amniotic fluid.
Materials and Methods: Amniotic fluid samples (n = 35) were obtained, and the number and size of viable
amniotic fluid cells (AFCs) were analyzed. Small AFCs (SAFCs) and large AFCs (LAFCs) were isolated using a
sterile 10-μm pore size strainer. Hoechst 33342 dye exclusion assay, flow cytometry analysis, reverse transcriptase
polymerase chain reaction and immunocytochemistry were used to analyze the characteristics of SAFCs and LAFCs.
Results: The mean concentration of viable AFCs from 16 to 21 weeks of gestation was 0.3 × 105, 0.8 × 105,
1.1 × 105, 1.3 × 105, 1.0 × 105 and 1.0 × 105 cells/mL respectively. The mean percentage of SAFCs from 16 to 21
weeks of gestation was 27.3%, 40.5%, 49.7%, 60.2%, 41.0% and 58.2%, respectively. The Hoechst 33342 efflux
phenomenon was obvious among SAFCs but was rare in the LAFC population. Flow cytometry analyses showed
that cell surface antigen expression on LAFCs and SAFCs were positive for CD29, CD44, CD73, CD90, CD166 and
HLA-I, but negative for CD31, CD34, CD45, CD117 and HLA-II. Importantly, Nanog, Oct-4, ABCG2 and SOX2
expression in cells was easily detectable among the SAFC population. Expression of Nanog and ABCG2 was not
observed among LAFCs.
Conclusion: Amniotic fluid contains a SP that was found mostly among the SAFCs. Enriched SP cells isolated by
the efflux of Hoechst 33342 could be a novel and promising source of pluripotent-like amniotic derived stem cells
for cellular therapy in the near future. [Taiwan J Obstet Gynecol 2010;49(2):139–144]
Key Words: amniotic fluid cells, amniotic fluid-derived stem cells, side population
*Correspondence to: Dr Ming-Song Tsai, Prenatal
Diagnosis Center, Department of Obstetrics and
Gynecology, Cathay General Hospital, 280, Jen-Ai
Road, Section 4, Taipei, 106, Taiwan.
E-mail: mstsai@cgh.org.tw
Accepted: September 23, 2009
alternative source of multipotent stem cells for the
treatment of neurodegenerative disorders and central
nervous system injuries [5].
The side population (SP) is a particular cell popu-
lation enriched in primitive and undifferentiated stem
cells. The isolation and enrichment of a SP fraction is
based on the efflux of the fluorescent dye, Hoechst
33342, as reported by Goodell et al [6] in 1996. Most
researchers consider that the SP is an enriched source
of stem cells for cellular therapy. Although SP cells
have been isolated from various adult tissues such as
hematopoietic bone marrow, skeletal muscle, brain,
liver, pancreas, lung, heart and kidney [7–9], there have
been no published reports of isolated SP cells from
human amniotic fluid to date.
In this study, we report a population of small amni-
otic fluid cells (SAFCs) that had Hoechst 33342 efflux
capacity and express common markers of pluripotent
stem cells.
Materials and Methods
Cell size analysis of viable amniotic fluid cells
A total of 2–3 mL of amniotic fluid was obtained by
routine amniocentesis at 16–20 weeks of gestation for
fetal karyotype analysis. After centrifugation, cells were
suspended in phosphate buffered saline (PBS) (Sigma,
St. Louis, MO, USA) and the size of viable amniotic
fluid cells (AFCs) was analyzed with a Cedex HiRes Cell
Analyzer (Roche Innovatis, Bielefeld, Germany) follow-
ing the manufacturer’s instructions. The institutional
review board of Cathay General Hospital approved this
protocol (CGHIRB no. CT9558), and each patient gave
written informed consent.
Isolation of a subpopulation of SAFCs
Dead epithelial cells were removed from the amniotic
fluid with a 40-μm pore size strainer. The sterile 10-μm
strainer (Millipore, Bedford, MA, USA) was used to
isolate smaller cells from native AFCs. The cells that
passed through the strainer were SAFCs, and those
that were retained were resuspended and collected as
large AFCs (LAFCs). Both the SAFCs and LAFCs were
analyzed. AFCs were suspended in minimum essential
medium alpha, (Hyclone, Logan, UT, USA) containing
20% (vol/vol) fetal bovine serum (FBS) (Hyclone), basic
fibroblast growth factor (R&D Systems, Minneapolis,
MN, USA) at 4 ng/mL, penicillin at 100 U/mL and strep-
tomycin (Sigma) at 100 μg/mL, and were incubated at
37°C in a 5% humidified CO2 atmosphere. The non-
adherent cells in the supernatant medium were removed
3 days after seeding, and the culture medium was
changed twice a week. When the cells reached 90% con-
fluence, they were washed, harvested with 0.05% trypsin-
EDTA (Sigma) and passaged at a ratio of 1:3 to 1:4.
Hoechst 33342 dye exclusion assay
Both the SAFCs and LAFCs were centrifuged at 200g
for 10 minutes, and incubated in minimum essential me-
dium alpha with 5% FBS and 5 μg/mL Hoechst (Sigma)
at 37°C for 1 hour. After PBS washing, the positive
stained cells were observed under fluorescence phase-
contrast microscopy.
Flow cytometry analysis
For characterization of SAFCs, the cells were trypsinized
and resuspended in PBS. After fixing with 1% methanol,
the cells were blocked in 1% bovine serum albumin
(Sigma) with 0.1% FBS for 1 hour at room temperature,
then washed with three volumes of PBS. For direct analy-
sis, cells were incubated with the following mouse
anti-human antibodies: CD26-FITC, CD29-PE, CD31-
FITC, CD34-PE, CD44-FITC, CD45-FITC, CD73-PE,
CD90-FITC, CD117-PE, CD166-PE, HLA-ABC-PE and
HLA-DR-PE (all from Becton-Dickinson, San Jose, CA,
USA). The analysis was performed on a FACSCalibur
flow cytometer (BD Bioscience, San Jose, CA, USA)
with at least 30,000 events recorded.
Reverse transcriptase-polymerase chain reaction
The SAFCs were frozen at –80°C to release nucleic acids
for analysis. The reverse transcriptase-polymerase chain
reaction (RT-PCR) was performed using OneStep assay
kits (Qiagen, Santa Clarita, CA, USA), following the
manufacturer’s instructions, and the expression of β-
actin was used for normalizing sample templates. The
PCR amplification was performed over 35 cycles with
specific primers for β-actin (forward, 5-GCA CTC TTC
CAG CCT TCC TTC C-3; reverse, 5-TCA CCT TCA
CCG TTC CAG TTT TT-3), Sox2 (forward, 5-AGA ACC
CCA AGA TGC ACA AC-3; reverse, 5-GGG CAG CGT
GTA CTT ATC CT-3), Oct-4 (forward, 5-CGT GAA
GCT GGA GAA GGA GAA GCT G-3; reverse, 5-CAA
GGG CCG CAG CTT ACA CAT GTT C-3), Nanog (for-
ward, 5-GCG CGG TCT TGG CTC ACT GC-3; reverse,
5-GCC TCC CAA TCC CAA ACA ATA CGA-3); ABCG2
(forward, 5-AGT TCC ATG GCA CTG GCC ATA-3;
reverse, 5-TCA GGT AGG CAA TTG TGA GG-3). The
PCR products were subjected to electrophoresis on
1.3% (wt/vol) agarose gels and visualized by ethidium
bromide staining.
Immunocytochemical staining
Fresh AFCs were fixed with 4% paraformaldehyde
(Merck, Darmstadt, Germany) and permeabilized with
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0.1% Triton X-100 (Sigma). After blocking with 10%
normal blocking serum (derived from the same species
as the secondary antibody) in PBS for 30 minutes, cells
were incubated with primary antibodies against
ABCG2, Nanog, Oct-4 or Nestin (all from Chemicon,
Temecula, CA, USA) for 1 hour. After having been
washed twice with PBS, cells were incubated with a
fluorescein isothiocyanate-conjugated secondary anti-
body (Vector Laboratories, Burlingame, CA, USA) for
1 hour at room temperature. The resulting immunore-
active cells were visualized by fluorescence microscopy.
Results
In the initial experiments, we used a Cedex HiRes Cell
Analyzer to assess the number of viable AFCs in native
second-trimester amniotic fluid. Two subpopulations
of viable AFCs were easily identified by their difference
in size. The average diameter of the small and large cell
populations was 5 μm (range, 3–8 μm) and 12 μm
(range, 10–20 μm), respectively (Figure 1A). The sub-
population of viable SAFCs could be isolated using a
10-μm pore size strainer as shown in Figure 1B. The
mean concentration of viable AFCs was 0.3 × 105 cells/
mL at 16 weeks, 0.8 × 105 cells/mL at 17 weeks, 1.1 ×
105 cells/mL at 18 weeks, 1.3 × 105 cells/mL at 19 weeks,
1.0 × 105 cells/mL at 20 weeks, and 1.0 × 105 cells/mL
at 21 weeks (Figure 2A). The mean percentage of SAFCs
was 27.3% at 16 weeks, 40.5% at 17 weeks, 49.7% at
18 weeks, 60.2% at 19 weeks, 41.0% at 20 weeks, and
58.2% at 21 weeks (Figure 2B).
We observed a subpopulation of SAFCs that had the
capacity to exclude Hoechst 33342, thereby demon-
strating the existence of a SP among SAFCs derived from
fresh second-trimester amniotic fluid (Figure 3A). 
Hoechst 33342 efflux in LAFCs was rare (Figure 3B).
The Table outlines the specific surface antigenic char-
acteristics of the cultured SAFCs and LAFCs at passage
4 as determined by flow cytometry. The analyses showed
that the cells of these two populations were positive
for CD29, CD44, CD73, CD90, CD166 and HLA-I, but
negative for CD31, CD34, CD45, CD117 and HLA-II.
The difference between these two cell types was in the
expression of CD26, where LAFCs strongly expressed this
molecule after culturing but SAFCs were only weakly
positive. Further characterization studies were performed
using RT-PCR and immunocytochemical staining for
the detection of Nestin, a marker of neural stem cells,
and ABCG2, Nanog, Oct-4 and Sox2, markers of plu-
ripotent stem cells. LAFCs expressed high levels of Sox2
and low levels of Oct-4, whereas SAFCs were positive
for Nanog, Oct-4 and SOX2 by RT-PCR (Figure 4).
However, only SAFCs expressed Nestin, ABCG2 and
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Figure 1. Viable amniotic fluid cells (AFCs) were analyzed with a Cedex HiRes Cell Analyzer (Roche Innovatis, Bielefeld,
Germany). (A) Two populations of AFCs were identified. The median cellular diameters of small and large AFCs were 5 μm
and 13 μm, respectively. (B) The small AFC population was isolated using a 10-μm strainer.
Nanog, as determined by immunocytochemical staining
(Figure 5).
Discussion
Prusa et al [10] were the first to report evidence of
human amniotic fluid containing stem cells in 2003.
They identified Oct-4-expressing cells in human amni-
otic fluid and proposed that these might be a new source
for pluripotent-like stem cells with the added benefit
that their use might avoid the ethical issues associated
with the use of human embryonic stem cells [10]. In
the same year, in ‘t Anker et al [11] demonstrated that
human amniotic fluid was an abundant source of fetal
mesenchymal stem cells (MSCs), and these cells exhib-
ited a phenotype and multilineage differentiation poten-
tial similar to that of bone marrow-derived MSCs. They
suggested that these amniotic fluid-derived MSCs could
be used for cotransplantation in conjunction with um-
bilical cord blood-derived hematopoietic stem cells [11].
In 2004, Tsai et al [4] successfully obtained AFMSCs
using a novel two-stage culture protocol without inter-
fering with the process of fetal karyotyping. In that
study, the authors were able to demonstrate that
AFMSCs could be expanded rapidly, and maintained
the capacity to differentiate into multiple cell types such
as adipocytes, osteoblasts and neurons in vitro [4]. In
addition to constituting a breakthrough in obtaining
human fetal stem cells from non-adherent cells of a
backup culture, this valuable discovery also offers a solu-
tion to the ethical dilemmas associated with obtaining
stem cells from human embryos and fetuses.
In the present preliminary study, we further demon-
strated that second-trimester amniotic fluid contains
two subpopulations of viable AFCs, the LAFCs and
SAFCs, which can be easily separated courtesy of the
difference in their cellular diameter. Both the LAFC and
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Figure 2. The numbers of viable amniotic fluid cells (AFCs) from 16 to 21 weeks of gestation. (A) The mean numbers of viable
AFCs at each week. (B) The mean percentage of small AFCs at each week.
A B
Figure 3. Overlay of brightfield and ultraviolet images displaying the positive Hoechst 33342 efflux phenomenon among the
small amniotic fluid cells (AFCs). (A) Hoechst 33342 exclusion was not noted in large AFCs. (B) The arrows indicate Hoechst
33342 excluding cells in small AFCs.
SAFC populations have the same phenotypic character-
istics, and these are similar to MSCs derived from other
sources such as first-trimester fetal tissues [12,13], term
umbilical cord blood [14,15], and placenta [16,17]
which are positive for CD29, CD44, CD73, CD90,
CD166 and HLA-I, but negative for CD31, CD34,
CD45, CD117 and HLA-II. The only difference in cell
surface antigen expression between these two popula-
tions involved CD26. It was present at a high levels on
the surface of LAFCs, but maintained at low levels on
SAFCs after culturing. However, both LAFCs and SAFCs
can be expanded rapidly and maintain the capacity 
to differentiate into multiple cell types in vitro, which 
is the same as for AFMSCs as described in previous
publications [4,5]. Importantly, SAFCs contain a sub-
population of pluripotent-like stem cells that expressed
high levels of Nanog, a gatekeeper of pluripotency in
human embryonic stem and carcinoma cells which pre-
vents their differentiation into extraembryonic endoderm
and trophectoderm lineages, and Oct-4, a transcrip-
tion factor expressed in embryonic stem cells, reflecting
a key role in the maintenance of stem cell pluripotency
in vivo and in vitro [5,10]. Only a few Oct-4-expressing
cells were found amongst the LAFCs. Whether LAFCs
and SAFCs are stem cells derived from different fetal
tissues or from the same fetal origin at different stages
of cell maturation is an issue worth further investigation.
The ATP-binding cassette (ABC) transporters rep-
resent a family of proteins with the capacity to bind ATP
as an energy source to transport endogenous or exoge-
nous molecules across the cellular membrane. ABCG2,
a member of the ABC transporter protein family and
also a molecular determinant of SP phenotype, has been
identified in the placenta, brain, kidney, intestine, liver,
testis, and ovaries. There is increasing evidence show-
ing that ABC transporters repress the maturation and
differentiation of stem cells [18–21].
In addition to the ability to exclude Hoechst 33342
dye, SAFCs also expressed ABCG2, suggesting that
SAFCs may contain a subpopulation of primitive and
undifferentiated stem cells with pluripotent potential.
This original discovery indicates that SP cells truly exist
in the native human amniotic fluid and are mostly found
among the SAFC population, which is consistent with
the notions that SP cells are smaller than non-SP cells
as described by Benchaouir et al [22], and that small
cell size is a stem cell characteristic as acknowledged
by Paiva et al [23].
Based on these findings, utilizing Hoechst 33342 dye
efflux activity to isolate SP cells from amniotic fluid by
flow cytometry could become a novel and promising
strategy for isolating enriched amniotic fluid-derived
stem cells, both for cellular therapy and for stem cell
engineering in the future.
In 2007, De Coppi et al [24] isolated the c-kit
(CD117) positive population by immunoselection from
second-trimester amniotic fluid samples and demon-
strated that amniotic fluid-derived stem cells have
pluripotent potential like embryonic stem cells, and are
able to differentiate into adipogenic, osteogenic, myo-
genic, endothelial, neurogenic and hepatic lineages.
Whether the SP cells of amniotic fluid have the same
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Table. Phenotypic characteristics of small and large
amniotic fluid cells (AFCs)
Small AFC (P4) Large AFC (P4)
CD26 +/− +
CD29 + +
CD31 − −
CD34 − −
CD44 + +
CD45 − −
CD73 + +
CD90 + +
CD117 − −
CD166 + +
HLA-I − −
HLA-II + +
P4 = passage 4.
Nanog
Sox2
Oct-4
β-actin
1 2 3 4 5 6 7
Figure 4. Reverse transcriptase-polymerase chain reaction
analyses of the common embryonic stem cell markers in
large amniotic fluid cells (AFCs) and small AFCs. Small AFCs
expressed Nanog, Oct-4, and SOX2 mRNA at high levels
(lanes 1–3: three individual small AFCs); large AFCs
expressed Sox 2 at a high level and Oct-4 mRNA at a low
level, and did not express Nanog mRNA (lanes 4–6: three
individual large AFCs). Lane 7: negative control.
ABCG2 NestinNanog 
A B C
Figure 5. Immunocytochemical analyses reveal that small
amniotic fluid cells populations contain (A) ABCG2- (arrow),
(B) Nanog- (arrow) and (C) Nestin-expressing cells (arrow).
pluripotent potential and are abundant enough for cel-
lular therapy is an interesting issue that requires further
exploration and is under investigation.
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